Health&Life Co

Health&Life Co Financing Cash Flow

The Net Financing Cash Flow of Health&Life Co (1781.TWO) as of Nov 6, 2026 is 75.77 M TWD. In the previous year, Net Financing Cash Flow was 40.66 M TWD — a change of 86.37% (higher).

Financing Cash Flow

75.77 MTWD

YoY

86.37%

Last updated:

Net Financing Cash Flow of Health&Life Co is 2020 75.77 M TWD. Net Financing Cash Flow of Health&Life Co was 2019 40.66 M TWD. It decreases by 86.37% higher compared to the previous year.

The Health&Life Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2014
-38.46 M TWD
Jan 1, 2015
30,000.00 TWD
Jan 1, 2016
-24,000.00 TWD
Jan 1, 2017
3.49 M TWD
Jan 1, 2018
87.42 M TWD
Jan 1, 2019
40.66 M TWD
Jan 1, 2020
75.77 M TWD
The Health&Life Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
75.77 MTWD+86.37%
40.66 MTWD-53.49%
87.42 MTWD+2,401.86%
3.49 MTWD-14,658.33%
-24,000.00TWD-180.00%
30,000.00TWD-100.08%
-38.46 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Net Financing Cash Flow of Health&Life Co is 75.77 M TWD in 2020.

Net Financing Cash Flow of Health&Life Co changed from 40.66 M TWD to 75.77 M TWD, representing a 86.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Health&Life Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Health&Life Co

All Key Metrics — Health&Life Co